VELCADE Update

posted November 22, 2011

FDA-Approved Update Sustained Overall Survival Advantage With VELCADE^® (bortezomib) (5-Year Median Follow-up) in Previously Untreated Multiple Myeloma - for more informamtion click here: VELCADE